Business NewsProduct News

MEDRIO EPRO CAPTURES PATIENT OUTCOMES, SHARES IN REAL-TIME

 

Patient reported outcomes (PRO) help to assess quality of life (QOL), efficacy and patient safety around the clock, and have become a staple in modern clinical research.

However, it can be challenging to set up an electronic patient reported outcomes (ePRO) platform that is compliant, simple to use, adaptable to any device and region and able to sync directly with your electronic data capture (EDC).

Medrio ePRO, an ePRO application available via tablet or web browser, handles all the complexities of PRO data, from flexible automated notifications and data collection to the construction of popular QOL formats. It allows rapid setup and deployment of surveys across the globe.

The combination of these functionalities leads to a simpler, more affordable process for running clinical trials, providing you more control over costs, timelines and patient safety.

It streamlines in-clinic data collection:

  • Accelerate the collection of PRO in-clinic with a straightforward tablet app.
  • Eliminate the need to print, manage and store paper.
  • Support common PRO formats such as: EQ5D, Bristol Stool Scale, CREST.BD, and more (subject to copyright).

The functions also improve the patient experience:

  • Collect data at home, in-clinic, at work or anywhere with an Internet connection.
  • Improve compliance through data collection at regular intervals, without the need for a clinic visit.
  • Automate reminders with relative or absolute time-based triggers.

Incorporate PRO into database for immediate monitor access. Easily segment and deploy region-specific content, improve patient safety and AE detection with real-time monitoring, and lock databases faster without paper SDV processing.

Though EDC has been around a long time now, it only recently became established as essentially standard in clinical data management. Strong support services have helped to humanize the process of adopting the technology and overcome some of the resistance that has often hindered that process. VTN

READ MORE: medrio.com

 

 

Previous post

CENTERLINE BIOMEDICAL COMPLETES FIFTH STUDY ON IOPS SURGICAL NAVIGATION UNIT

Next post

SURMODICS GETS FDA OK TO SELL TELEMARK MICROCATHETHETER

Camden Lawless

Camden Lawless